Patents by Inventor Laura A. Maile

Laura A. Maile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 9868787
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: January 16, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Antagonists of IAP-SHPS1 interaction
    Patent number: 9475882
    Abstract: Provided herein is technology relating to antagonists that inhibit, reduce, or minimize the interaction of integrin associated protein (IAP) with Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1 (SHPS1) and particularly, but not exclusively, to compositions comprising such antagonists and methods of treatment comprising administering such antagonists.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: October 25, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor-I
    Publication number: 20150259421
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Application
    Filed: May 28, 2015
    Publication date: September 17, 2015
    Inventors: David R. CLEMMONS, Laura A. Maile
  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 9068000
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: June 30, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Method for Inhibiting Cellular Activation by Insulin-Like Growth Factor-1
    Publication number: 20140141002
    Abstract: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
    Type: Application
    Filed: November 8, 2013
    Publication date: May 22, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
    Patent number: 8613922
    Abstract: A method of inhibiting cellular activation by insulin-like growth factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: December 24, 2013
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Monoclonal Antibodies for Enhancing or Inhibiting Insulin-Like Growth Factor-I
    Publication number: 20120269816
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Application
    Filed: May 17, 2012
    Publication date: October 25, 2012
    Inventors: David R. Clemmons, Laura A. Maile
  • Method for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 8206706
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: February 18, 2009
    Date of Patent: June 26, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 8187595
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: May 29, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
    Publication number: 20120039896
    Abstract: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
    Type: Application
    Filed: August 26, 2011
    Publication date: February 16, 2012
    Inventors: David R. Clemmons, Laura A. Maile
  • METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
    Publication number: 20100215640
    Abstract: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis, diabetic retinopathy or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
    Type: Application
    Filed: November 12, 2009
    Publication date: August 26, 2010
    Inventors: David R. Clemmons, Laura A. Maile
  • Method for enhancing or inhibiting insulin-like growth factor-I
    Patent number: 7723483
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: May 25, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: David R. Clemmons, Laura A. Maile
  • MONOCLONAL ANTIBODIES FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I
    Publication number: 20090280127
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Application
    Filed: July 7, 2009
    Publication date: November 12, 2009
    Inventors: David R. Clemmons, Laura A. Maile
  • METHOD FOR ENHANCING OR INHIBITING INSULIN-LIKE GROWTH FACTOR-I
    Publication number: 20090226452
    Abstract: The present invention provides ?V?3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
    Type: Application
    Filed: February 18, 2009
    Publication date: September 10, 2009
    Applicant: University of North Carolina
    Inventors: David R. Clemmons, Laura A. Maile
  • METHOD FOR INHIBITING CELLULAR ACTIVATION BY INSULIN-LIKE GROWTH FACTOR-1
    Publication number: 20080160013
    Abstract: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
    Type: Application
    Filed: September 28, 2007
    Publication date: July 3, 2008
    Inventors: David R. Clemmons, Laura A. Maile
  • Method for inhibiting cellular activation by insulin-like growth factor-1
    Publication number: 20040213792
    Abstract: A method of inhibiting cellular activation by Insulin-like Growth Factor-1 (IGF-1) in a subject in need thereof (e.g., a subject afflicted with cancer, atherosclerosis or other disease) comprises administering an antagonist that inhibits the binding of IAP to SHPS-1 to the subject in an amount effective to inhibit cellular activation by IGF-1. Compounds and compositions for carrying out such methods are also described.
    Type: Application
    Filed: April 24, 2003
    Publication date: October 28, 2004
    Inventors: David R. Clemmons, Laura A. Maile